	US 12,077,597 B2
	Anti-CD5 antibodies and methods of use thereof
Claudine Vermot-Desroches, Dardilly (FR); Hélène Rouquette, Paris (FR); and Benoît Milcent, Paris (FR)
Assigned to INTERNATIONAL-DRUG-DEVELOPMENT-BIOTECH, Lyons (FR)
Filed by INTERNATIONAL-DRUG-DEVELOPMENT-BIOTECH, Lyons (FR)
Filed on Nov. 24, 2021, as Appl. No. 17/534,707.
Prior Publication US 2023/0159654 A1, May 25, 2023
Int. Cl. C07K 16/28 (2006.01); A61K 39/00 (2006.01); A61P 35/00 (2006.01); A61P 35/02 (2006.01)

CPC C07K 16/2896 (2013.01) [A61P 35/00 (2018.01); A61P 35/02 (2018.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/52 (2013.01); C07K 2317/565 (2013.01); C07K 2317/732 (2013.01); C07K 2317/734 (2013.01)]

16 Claims

1. A pharmaceutical composition comprising a monoclonal antibody, or an antigen-binding fragment thereof, said antibody or fragment thereof specifically binding to CD5, wherein said antibody or fragment comprises a VL chain and a VH chain of the murine monoclonal antibody mR007, and wherein said VL and VH chains are selected from the group consisting of:

(1) a VL chain comprising the following three CDRs: a L-CDR1 comprising sequence SEQ ID NO: 1, a L-CDR2 comprising sequence RAS, a L-CDR3 comprising sequence SEQ ID NO: 2; and a VH chain comprising the following three CDRs: a H-CDR1 comprising sequence SEQ ID NO: 3, a H-CDR2 comprising sequence SEQ ID NO: 4, a H-CDR3 comprising sequence SEQ ID NO: 5;

(2) a VL chain comprising the following three CDRs: a L-CDR1 comprising sequence SEQ ID NO: 6, a L-CDR2 comprising sequence SEQ ID NO: 7, a L-CDR3 comprising sequence SEQ ID NO: 2; and a VH chain comprising the following three CDRs: a H-CDR1 comprising sequence SEQ ID NO: 8, a H-CDR2 comprising sequence SEQ ID NO: 9, a H-CDR3 comprising sequence SEQ ID NO: 10; and

(3) a VL chain comprising the following three CDRs: a L-CDR1 comprising sequence SEQ ID NO: 1, a L-CDR2 comprising sequence RAS, a L-CDR3 comprising sequence SEQ ID NO: 2; and a VH chain comprising the following three CDRs: a H-CDR1 comprising sequence SEQ ID NO: 11, a H-CDR2 comprising sequence SEQ ID NO: 4, a H-CDR3 comprising sequence SEQ ID NO: 10, and a pharmaceutically acceptable vehicle or excipient.